Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-05-29
1999-10-19
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142358, 514253, 514255, 544121, 544357, 544360, 544295, 544366, 544370, 544388, 544391, A61K 31495, C07D40112, C07D40312
Patent
active
059689382
ABSTRACT:
This invention relates to certain novel piperazine compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor in mammals, especially humans. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.
REFERENCES:
patent: 5464788 (1995-11-01), Bock et al.
patent: 5726172 (1998-03-01), Sparks et al.
patent: 5756504 (1998-05-01), Bock et al.
P.D. Williams et al., "Recent Advances in the Development of Oxytocin Receptor Antagonists" Current Pharmaceutical Design, (1996), vol. 2, pp. 41-48.
Evans et al, J. Med Chem. 36, pp. 3993-4005, 1993.
Bell Ian
Freidinger Roger M.
Guare, Jr. James P.
Sparks Michelle A.
Williams Peter D.
Bernhardt Emily
Durette Philippe L.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Piperazine oxytocin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine oxytocin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine oxytocin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055698